Cargando…
Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product
Coronavirus Disease 2019 (COVID-19) is a major public health problem worldwide with 5–10% hospitalization and 2–3% global mortality rates at the time of this publication. The disease is caused by a betacoronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The receptor-bind...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957997/ https://www.ncbi.nlm.nih.gov/pubmed/35350184 http://dx.doi.org/10.3389/fbioe.2022.839374 |
_version_ | 1784676854759686144 |
---|---|
author | Szabo, Miklos Sarkozy, Daniel Szigeti, Marton Farsang, Robert Kardos, Zsofia Kozma, Adam Csanky, Eszter Chung, Doo Soo Szekanecz, Zoltan Guttman, Andras |
author_facet | Szabo, Miklos Sarkozy, Daniel Szigeti, Marton Farsang, Robert Kardos, Zsofia Kozma, Adam Csanky, Eszter Chung, Doo Soo Szekanecz, Zoltan Guttman, Andras |
author_sort | Szabo, Miklos |
collection | PubMed |
description | Coronavirus Disease 2019 (COVID-19) is a major public health problem worldwide with 5–10% hospitalization and 2–3% global mortality rates at the time of this publication. The disease is caused by a betacoronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The receptor-binding domain (RBD) of the Spike protein expressed on the surface of the virus plays a key role in the viral entry into the host cell via the angiotensin-converting enzyme 2 receptor. Neutralizing monoclonal antibodies having the RBD as a target have the ability to inhibit angiotensin-converting enzyme 2 (ACE2) receptor binding, therefore, prevent SARS-CoV-2 infection, represent a promising pharmacological strategy. Bamlanivimab is the first anti-spike neutralizing monoclonal antibody, which got an emergency use authorization from the FDA for COVID-19 treatment. Albeit, bamlanivimab is primarily a neutralizing mAb, some of its effector function related activity was also emphasized. The effector function of antibody therapeutics is greatly affected by their N-linked carbohydrates at the conserved Fc region, possibly influenced by the manufacturing process. Various capillary gel electrophoresis methods are widely accepted in the biopharmaceutical industry for the characterization of therapeutic antibodies. In this paper we introduce a capillary gel electrophoresis based workflow for 1) size heterogeneity analysis to determine the presence/absence of the non-glycosylated heavy chain (NGHC) fragment (SDS-CGE); 2) capillary gel isoelectric focusing for possible N-glycosylation mediated charge heterogeneity determination, e.g., for excess sialylation and finally, 3) capillary gel electrophoresis for N-glycosylation profiling and sequencing. Our results have shown the presence of negligible amount of non-glycosylated heavy chain (NGHC) while 25% acidic charge variants were detected. Comprehensive N-glycosylation characterization revealed the occurrence of approximately 8.2% core-afucosylated complex and 17% galactosylated N-linked oligosaccharides, suggesting the possible existence of antibody dependent cell mediated cytotoxicity (ADCC) effector function in addition to the generally considered neutralizing effect of this particular therapeutic antibody molecule. |
format | Online Article Text |
id | pubmed-8957997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89579972022-03-28 Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product Szabo, Miklos Sarkozy, Daniel Szigeti, Marton Farsang, Robert Kardos, Zsofia Kozma, Adam Csanky, Eszter Chung, Doo Soo Szekanecz, Zoltan Guttman, Andras Front Bioeng Biotechnol Bioengineering and Biotechnology Coronavirus Disease 2019 (COVID-19) is a major public health problem worldwide with 5–10% hospitalization and 2–3% global mortality rates at the time of this publication. The disease is caused by a betacoronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The receptor-binding domain (RBD) of the Spike protein expressed on the surface of the virus plays a key role in the viral entry into the host cell via the angiotensin-converting enzyme 2 receptor. Neutralizing monoclonal antibodies having the RBD as a target have the ability to inhibit angiotensin-converting enzyme 2 (ACE2) receptor binding, therefore, prevent SARS-CoV-2 infection, represent a promising pharmacological strategy. Bamlanivimab is the first anti-spike neutralizing monoclonal antibody, which got an emergency use authorization from the FDA for COVID-19 treatment. Albeit, bamlanivimab is primarily a neutralizing mAb, some of its effector function related activity was also emphasized. The effector function of antibody therapeutics is greatly affected by their N-linked carbohydrates at the conserved Fc region, possibly influenced by the manufacturing process. Various capillary gel electrophoresis methods are widely accepted in the biopharmaceutical industry for the characterization of therapeutic antibodies. In this paper we introduce a capillary gel electrophoresis based workflow for 1) size heterogeneity analysis to determine the presence/absence of the non-glycosylated heavy chain (NGHC) fragment (SDS-CGE); 2) capillary gel isoelectric focusing for possible N-glycosylation mediated charge heterogeneity determination, e.g., for excess sialylation and finally, 3) capillary gel electrophoresis for N-glycosylation profiling and sequencing. Our results have shown the presence of negligible amount of non-glycosylated heavy chain (NGHC) while 25% acidic charge variants were detected. Comprehensive N-glycosylation characterization revealed the occurrence of approximately 8.2% core-afucosylated complex and 17% galactosylated N-linked oligosaccharides, suggesting the possible existence of antibody dependent cell mediated cytotoxicity (ADCC) effector function in addition to the generally considered neutralizing effect of this particular therapeutic antibody molecule. Frontiers Media S.A. 2022-03-08 /pmc/articles/PMC8957997/ /pubmed/35350184 http://dx.doi.org/10.3389/fbioe.2022.839374 Text en Copyright © 2022 Szabo, Sarkozy, Szigeti, Farsang, Kardos, Kozma, Csanky, Chung, Szekanecz and Guttman. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Szabo, Miklos Sarkozy, Daniel Szigeti, Marton Farsang, Robert Kardos, Zsofia Kozma, Adam Csanky, Eszter Chung, Doo Soo Szekanecz, Zoltan Guttman, Andras Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product |
title | Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product |
title_full | Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product |
title_fullStr | Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product |
title_full_unstemmed | Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product |
title_short | Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product |
title_sort | introduction of a capillary gel electrophoresis-based workflow for biotherapeutics characterization: size, charge, and n-glycosylation variant analysis of bamlanivimab, an anti-sars-cov-2 product |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957997/ https://www.ncbi.nlm.nih.gov/pubmed/35350184 http://dx.doi.org/10.3389/fbioe.2022.839374 |
work_keys_str_mv | AT szabomiklos introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product AT sarkozydaniel introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product AT szigetimarton introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product AT farsangrobert introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product AT kardoszsofia introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product AT kozmaadam introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product AT csankyeszter introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product AT chungdoosoo introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product AT szekaneczzoltan introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product AT guttmanandras introductionofacapillarygelelectrophoresisbasedworkflowforbiotherapeuticscharacterizationsizechargeandnglycosylationvariantanalysisofbamlanivimabanantisarscov2product |